Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 2/20 | 0.39 |
| ▸ | RET | P07949 | 4/20 | 0.39 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.36 |
| ▸ | PI4KA | P42356 | 3/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.32 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21758936 | 0.88 | PI4KB (0.35) | ACVRL1RETKDRPI4KBPI4KA | |
| SCHEMBL22107444 | 0.81 | ADORA2A (0.35) | ACVRL1PI4KBPI4KAPI4K2BPI4K2A | |
| SCHEMBL24633433 | 0.79 | TLR7 (0.33) | ACVRL1PI4KBPI4KAPI4K2BPI4K2A | |
| SCHEMBL25810040 | 0.78 | ADORA2A (0.33) | ACVRL1PI4KBPI4KAPI4K2BPI4K2A | |
| SCHEMBL22349649 | 0.77 | TLR7 (0.32) | ACVRL1PI4KBPI4KAPI4K2BPI4K2A | |
| SCHEMBL15912317 | 0.76 | CAPN1 (0.30) | — | |
| SCHEMBL23786397 | 0.76 | YTHDC1 (0.37) | ALDH1A1TSHRHSD17B10 | |
| SCHEMBL23679750 | 0.76 | PI4KA (0.35) | PI4KBPI4KAPI4K2BPI4K2AADORA2A | |
| SCHEMBL10120458 | 0.76 | PI4KA (0.39) | PI4KBPI4KAPI4K2BPI4K2AADORA2A | |
| SCHEMBL22326722 | 0.75 | PI4KA (0.37) | PI4KBPI4KAPI4K2BPI4K2AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| EP-4268824-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZINE DERIVATIVES USEFUL AS A MEDICAMENT | Manros Therapeutics (FR) | 2023-11-01 | — | — | EP | disclosed |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| EP-3621624-B1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| US-11472826-B2 | Acyclic antivirals | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-18 | — | — | US | disclosed |
| US-20220251135-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | BEONE MEDICINES I GMBH (CH) | 2022-08-11 | — | — | US | disclosed |
| WO-2017027645-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017027646-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | WO | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| US-9457039-B2 | 2′-disubstituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160045526-A1 | 2'-DISUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2016-02-18 | — | — | US | disclosed |
| US-9242988-B2 | 2′-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150274739-A1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | US | disclosed |
| US-9090642-B2 | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs | GILEAD SCIENCES, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20130281686-A1 | METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS | GILEAD SCIENCES, INC. (US) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | ACVRL1 2645/4885RET 1790/4885KDR 1753/4885 |
| US-11472826-B2 | Acyclic antivirals | PNP, DUT, TYMP | ACVRL1 1916/4885RET 4749/4885KDR 4618/4885 |
| US-20150274739-A1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | NSUN2, RNGTT, NT5C3B | ACVRL1 2211/4885RET 3543/4885KDR 3088/4885 |
| US-20130281686-A1 | METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS | PAICS, DPYD, PNP | ACVRL1 3529/4885RET 2418/4885KDR 4074/4885 |
| US-20160045526-A1 | 2'-DISUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | SLC28A2, SLC28A1, SLC29A2 | ACVRL1 3758/4885RET 2215/4885KDR 3259/4885 |
| US-20220251135-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, MAVS | ACVRL1 1824/4885RET 2969/4885KDR 2844/4885 |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | STING1, TLR9, CGAS | ACVRL1 2645/4885RET 1790/4885KDR 1753/4885 |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | ACVRL1 500/4885RET 3049/4885KDR 4190/4885 |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | STING1, IRF3, CGAS | ACVRL1 1254/4885RET 4024/4885KDR 1366/4885 |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | ACVRL1 575/4885RET 3598/4885KDR 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.